logo
The cannabis factory: How one doctor wrote 72,000 scripts in two years

The cannabis factory: How one doctor wrote 72,000 scripts in two years

The Age27-07-2025
A single doctor at Australia's largest medicinal cannabis company churned out 72,000 prescriptions to 10,000 patients in just two years, prompting fresh alarm about potentially unsafe prescribing practices in the booming sector.
The concerning scale of prescribing at Montu, documented in leaked reports, has been confirmed by the company after initial denials. The revelations have alarmed cannabis industry insiders pushing for stricter rules for the booming industry, and prompted federal Health Minister Mark Butler to warn of 'unscrupulous and possibly unsafe behaviour' in the sector.
Since Australia approved cannabis for medical use in 2016, a booming telehealth industry has emerged.
At the forefront is the Montu Group, which owns Alternaleaf clinics that employ medical staff — including 120 doctors and nurses paid per appointment — to prescribe via telehealth, and subsidiary Leafio, which dispenses the medication. Montu also has its own range of cannabis products (named 'Circle' and 'Sundaze') that its doctors prescribe, among other brands.
Leaked documents, along with interviews with 10 former Montu clinical staff, reveal concerns about a high-volume prescribing model. The records show how just eight of the company's doctors together issued 245,109 scripts in the two years to June 30 this year, an average of 295 scripts per doctor for a standard five-day working week.
The documents show Alternaleaf's busiest doctor saw 10,500 patients and issued 72,500 scripts in that two-year period. Another practitioner wrote 49,500 scripts for 4300 patients in just over two years, while a third issued nearly 40,000 scripts to 4000 patients.
The leaked data prompted an initial denial from Montu. A spokesman claimed the leaked figures were 'not accurate' and that in the last 12 months its doctors had issued an average of just 205 prescriptions to 80 different patients per week. 'There is no doctor at Montu prescribing anywhere near these levels,' the spokesperson said initially.
Asked by this masthead to re-check its records, Montu reversed its position and confirmed the top prescriber's numbers. The company attributed the performance to 'one outlier doctor, who is the highest prescriber at Alternaleaf and works more hours than any other doctor'.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Labor vows to ‘fight' as Trump threatens pharma tariffs
Labor vows to ‘fight' as Trump threatens pharma tariffs

Perth Now

time08-08-2025

  • Perth Now

Labor vows to ‘fight' as Trump threatens pharma tariffs

Health Minister Mark Butler says the Albanese government will 'fight for the PBS'. Martin Ollman / NewsWire Health Minister Mark Butler says the Albanese government will 'fight for the PBS'. Martin Ollman / NewsWire Credit: News Corp Australia The Albanese government is vowing to 'fight for the PBS' as Donald Trump tries to strongarm drugmakers into moving production to the US. The Pharmaceutical Benefits Scheme (PBS) is a list of federally subsidised medicines and a prized Labor invention. Health Minister Mark Butler last month introduced legislation that, if passed, would cap PBS-listed medicines at $25 from January 1, 2026. Aside from subsidising medicines, the scheme also compels firms to negotiate prices with the federal government, which helps keep products affordable. Celebrated as a cornerstone of the healthcare system in Canberra, the scheme is denounced by pharmaceutical lobbyists in Washington, who claim Australia is 'freeloading on American innovation'. One group, Pharmaceutical Research and Manufacturers of America (PhRMA), has explicitly urged the Trump administration to 'leverage ongoing trade negotiations' to influence Australia's PBS policies. But Anthony Albanese, Mr Butler and other ministers have ruled out budging on the PBS. 'We'll fight for our PBS and fight for the jobs of Australian manufacturers here,' Mr Butler told the ABC on Friday, noting most production is in Melbourne. Pharmaceutical exports to the US totalled north of $2bn in 2024, making it the biggest foreign market for Australian producers. Exports are mostly blood products and vaccines but also include packaged medicines and miscellaneous medical items, such as bandages. Though, as Mr Butler noted, the US still exported more to Australia and did so without tariffs. 'We have zero tariffs on those imports that we take from America companies,' he said. 'We're making the case that should continue in reverse. 'We should be able to continue to export our terrific blood and plasma products and medicines to Americans without what might be a 250 per cent tariff.' Camera Icon Health Minister Mark Butler says the Albanese government will 'fight for the PBS'. Martin Ollman / NewsWire Credit: News Corp Australia For the moment, Mr Trump's concern with the sector appears to be largely driven by bringing down prices in the US rather than punishing allies for having cheaper medicines. Last week, he wrote to 17 major pharmaceutical companies demanding they lower their prices for American consumers to bring them in line with prices overseas. A Rand Corporation report found that Americans pay nearly four times more than Australians for medicines and about three times more than the average in other developed economies. The answer, according to Mr Trump, is making pharmaceuticals in the US. Mr Trump's 250 per cent tariff threat was a warning shot to firms, but one that, if realised, would hit producers Down Under hard.

Labor vows to ‘fight' as Trump threatens pharma tariffs
Labor vows to ‘fight' as Trump threatens pharma tariffs

News.com.au

time08-08-2025

  • News.com.au

Labor vows to ‘fight' as Trump threatens pharma tariffs

The Albanese government is vowing to 'fight for the PBS' as Donald Trump tries to strongarm drugmakers into moving production to the US. The Pharmaceutical Benefits Scheme (PBS) is a list of federally subsidised medicines and a prized Labor invention. Health Minister Mark Butler last month introduced legislation that, if passed, would cap PBS-listed medicines at $25 from January 1, 2026. Aside from subsidising medicines, the scheme also compels firms to negotiate prices with the federal government, which helps keep products affordable. Celebrated as a cornerstone of the healthcare system in Canberra, the scheme is denounced by pharmaceutical lobbyists in Washington, who claim Australia is 'freeloading on American innovation'. One group, Pharmaceutical Research and Manufacturers of America (PhRMA), has explicitly urged the Trump administration to 'leverage ongoing trade negotiations' to influence Australia's PBS policies. But Anthony Albanese, Mr Butler and other ministers have ruled out budging on the PBS. 'We'll fight for our PBS and fight for the jobs of Australian manufacturers here,' Mr Butler told the ABC on Friday, noting most production is in Melbourne. Pharmaceutical exports to the US totalled north of $2bn in 2024, making it the biggest foreign market for Australian producers. Exports are mostly blood products and vaccines but also include packaged medicines and miscellaneous medical items, such as bandages. Though, as Mr Butler noted, the US still exported more to Australia and did so without tariffs. 'We have zero tariffs on those imports that we take from America companies,' he said. 'We're making the case that should continue in reverse. 'We should be able to continue to export our terrific blood and plasma products and medicines to Americans without what might be a 250 per cent tariff.' For the moment, Mr Trump's concern with the sector appears to be largely driven by bringing down prices in the US rather than punishing allies for having cheaper medicines. Last week, he wrote to 17 major pharmaceutical companies demanding they lower their prices for American consumers to bring them in line with prices overseas. A Rand Corporation report found that Americans pay nearly four times more than Australians for medicines and about three times more than the average in other developed economies. The answer, according to Mr Trump, is making pharmaceuticals in the US. Mr Trump's 250 per cent tariff threat was a warning shot to firms, but one that, if realised, would hit producers Down Under hard.

Australian news and politics live: Health Minister Mark Butler vows to defends Australia's PBS amid US threats
Australian news and politics live: Health Minister Mark Butler vows to defends Australia's PBS amid US threats

West Australian

time07-08-2025

  • West Australian

Australian news and politics live: Health Minister Mark Butler vows to defends Australia's PBS amid US threats

Scroll down for the latest news and updates. Health Minister Mark Butler says the Australian Government is committed to defending both the Pharmaceutical Benefits Scheme (PBS) and the jobs supported by local drug manufacturers. With growing pressure from the US threatening tariffs as high as 250 per cent on pharmaceutical exports, Mr Butler insists Australia will fight to maintain its affordable medicines system while protecting its exporters. 'We'll fight for our PBS and fight for the jobs that Australian manufacturers here, particularly in Melbourne, down in Melbourne CSL, have provided to Australian families for years,' he told Sunrise on Friday morning. 'Exporting great medicines, blood and plasma products to the United States under the US free trade agreement. 'The US exports more pharmaceuticals to Australia. We have zero tariffs on those imports that we take from American companies. We're making the case that should continue in reverse. 'We should be able to continue to export our terrific blood and plasma products and medicines to Americans without what might be a 250 per cent tariff. Not just on Australia but on every country around the world seeking to export pharmaceuticals to the Americans.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store